GBA1 and Parkinson disease: On the other hand, LRRK2 kinase inhibitors restored GCase activity in neurons that carry mutations in LRRK2 or GBA1, and rescued neurons from PD-associated phenotypes including accumulation of dopamine oxidization products and accumulation of phospho-S129 alpha synuclein.